Loading...
Market
How will Biogen's stock price compare to its competitors by December 31, 2024?
2
Resolution / Starting Odds
Higher than competitors • 25%
On par with competitors • 25%
Lower than competitors • 25%
Significantly lower than competitors • 25%
Stock price data from financial market sources like Nasdaq or Yahoo Finance
Story
EU Regulator Rejects Leqembi for Early Alzheimer's Disease; Biogen Stock Falls 6.7%
Jul 26, 2024, 11:23 AM
The European Union's drugs regulator has rejected Eisai and Biogen's Alzheimer's drug, Leqembi, for early Alzheimer's disease, citing concerns over its safety profile. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion, stating that the observed effect of Leqembi on delaying cognitive decline does not outweigh the risk of serious adverse events. The decision also noted the drug's slight advantage over placebo on a clinical dementia rating scale. This contrasts with the U.S. regulators, who have granted full approval for the drug. The rejection is a significant setback for Eisai and Biogen, who were seeking to expand sales in the European market. Following the announcement, Biogen's stock fell by 6.7% in pre-market trading.
View original story
Similar markets
Outperforms competitors • 25%
Matches competitors • 25%
Underperforms competitors • 25%
Significantly underperforms competitors • 25%
Top 5 • 25%
Top 10 • 25%
Top 20 • 25%
Below Top 20 • 25%
Increase by more than 5% • 25%
Decrease by more than 5% • 25%
Fluctuate within ±5% • 25%
No significant change • 25%
Outperform by more than 5% • 25%
Perform within 5% of S&P 500 • 25%
Underperform by 1-5% • 25%
Underperform by more than 5% • 25%
Below $2.4 billion • 25%
$2.4 billion to $2.5 billion • 25%
$2.5 billion to $2.6 billion • 25%
Above $2.6 billion • 25%
Outperforms • 33%
Performs similarly • 34%
Underperforms • 33%
Outperforms major competitors • 25%
Performs similarly to major competitors • 25%
Underperforms major competitors • 25%
Significantly underperforms major competitors • 25%
Below $16.10 • 25%
$16.10 to $16.60 • 25%
$16.61 to $17.10 • 25%
Above $17.10 • 25%
Outperforms all • 25%
Outperforms some • 25%
Matches performance • 25%
Underperforms all • 25%
Novartis outperforms competitors • 25%
Novartis performs equally as competitors • 25%
Novartis underperforms competitors • 25%
Stock performance is inconclusive • 25%